OOIR: Observatory of International Research

Papers

(The H4-Index of European Respiratory Journal is 58. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Soteria: deliverance from harm?	1342
The right ventricle tamed	877
Unravelling the “frequent exacerbator” phenotype in cystic fibrosis	238
Chymase-1: a “MAST”-er switch in COPD?	213
If your patient with asthma wheezes when sitting or lying quietly, lung function testing may reveal small airway disease	201
Missing airways, ventilation defects and conductive airway physiology in asthma	187
Epigenome-wide association studies: the exposures of yesterday form the methylations of tomorrow	180
A breath of the future: a novel human model for COPD and beyond	166
The lung that rules the heart	163
Randomised controlled trials utilisingF_ENOto manage asthma: is it time to acknowledge that “one size does not fit all”?	151
Moving the needle on proteasome inhibitor-induced pulmonary arterial hypertension: a definite maybe	146
Gene–environment interaction at 17q12–q21 locus and its role in asthma pathogenesis	145
Antiviral CD8⁺T-cell immune responses are impaired by cigarette smoke and in COPD	131
Haemodynamic phenotypes of pulmonary hypertension associated with left heart disease: a moving target	129
Lymphoma in patients with asthma treated with dupilumab: much ado about nothing?	126
Combining rituximab with mycophenolate for the treatment of interstitial lung disease	121
From spatial transcriptomics to mouse model: the (re-)emergence of ductal myofibroblasts as a new cellular target in idiopathic pulmonary fibrosis	117
Novel pathomechanisms of ventilator-induced neonatal lung injury: new targets to overcome ongoing challenges	114
Pleural fluid proteomics from patients with pleural infection shows signatures of diverse neutrophilic responses: The Oxford Pleural Infection Endotyping Study (TORPIDS-2)	113
Shear-wave elastography-guided transthoracic biopsy for lung lesions: a randomized controlled trial	112
Arousal threshold modifies the effect of CPAP on executive function among individuals with obstructive sleep apnoea	110
Idiopathic pleuroparenchymal fibroelastosis: three-dimensional computed tomography assessment of upper-lobe lung volume	108
Collaboration between explainable artificial intelligence and pulmonologists improves the accuracy of pulmonary function test interpretation	107
Plasma cells: a feasible therapeutic target in pulmonary fibrosis?	105
Fibroblast heterogeneity in pulmonary fibrosis: a new target for therapeutics development?	102

Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis	97
Natural decline in pulmonary function following bilateral lung transplantation: a single-centre study	96
Extensive acute and sustained changes to neutrophil proteomes post-SARS-CoV-2 infection	96
Salivary polyreactive antibodies andHaemophilus influenzaeare associated with respiratory infection severity in young children with recurrent respiratory infections	91
A normal BNP does not reliably exclude pulmonary hypertension in interstitial lung disease	84
Prenatal exposure to greenness and early childhood pneumonia: a nationwide study in Japan	83
Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing of M. tuberculosis	81
Long-term radiological and pulmonary function abnormalities at 3 years after COVID-19 hospitalisation: a longitudinal cohort study	80
Revisiting asthma pharmacotherapy: where do we stand and where do we want to go?	80
Treatment algorithm for pulmonary arterial hypertension	79
RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD	77
Tricuspid regurgitation in pulmonary arterial hypertension: a right ventricular volumetric and functional analysis	77
Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial	76
Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms	75
Invisibility of breathlessness in clinical consultations: a cross-sectional, national online survey	74
A patient-tailored approach for corticosteroid treatment in COVID-19: still not there yet	72
Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor	72
Genomic classifier for usual interstitial pneumonia combined with bronchoalveolar lavage cellular profile: potential use in the clinical management of new onset ILD?	71
Lunsekimig's bispecific targeting of IL-13 and TSLP in asthma: dual targets for synergistic effects?	70
Real-world monitoring of elexacaftor/tezacaftor/ivacaftor trough concentrations in adults with cystic fibrosis	69
Risk of rifampicin resistance emergence after incomplete first-line tuberculosis treatment	65
The impact of oral anticoagulants on idiopathic pulmonary fibrosis risk and prognosis: a population study	65
Challenges in harmonising terms and patterns among interstitial pneumonias: enter idiopathic bronchiolocentric interstitial pneumonia	65
No exposure left behind: time to pay attention to children's chemical environment in lung development	65
Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis	64
Benralizumab in severe eosinophilic asthma by previous biologic use and key clinical subgroups: real-world XALOC-1 programme	64
The association of eicosanoids and eicosanoid-related metabolites with pulmonary hypertension	64
Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension	61
Particulate matter-related ITIH4 deficiency is associated with an emphysema phenotype of COPD through JNK-dependent and JNK-independent signalling	60
The association between immunosuppressants and outcomes of COVID-19	60
Small packages but big insights: extracellular vesicles as biomarkers in interstitial lung disease associated with systemic sclerosis	59
Associations of hiatus hernia with CT-based interstitial lung changes: the MESA Lung Study	59
The limits of normal of pulmonary arterial wedge pressure	59